| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | ADRX, INC. | 515 MARIN ST | THOUSAND OAKS | CA | 91360-4116 | VENTURA | USA | R43TR004056 | Development of a Blood-based Diagnostic for Early Detection of Transthyretin Amyloidosis | 000 | 1 | NIH | 12/13/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | ADRX, INC. | 515 MARIN ST | THOUSAND OAKS | CA | 91360-4116 | VENTURA | USA | R43AG073018 | Brain-penetrant chemical disaggregators of tau fibrils as therapeutics for Alzheimer's Disease | 000 | 1 | NIH | 7/12/2024 | $0 |
| | 2024 | 2022 | ADRX, INC. | 515 MARIN ST | THOUSAND OAKS | CA | 91360-4116 | VENTURA | USA | R43GM145259 | Therapeutic Immunodepletion of a Transthyretin Aggregation Intermediate | 000 | 1 | NIH | 5/30/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,002,910 ) |
| | 2022 | 2022 | ADRX, INC. | 515 MARIN ST # 314 | THOUSAND OAKS | CA | 91360-4259 | VENTURA | USA | R43AG073018 | Brain-penetrant chemical disaggregators of tau fibrils as therapeutics for Alzheimer's Disease | 001 | 1 | NIH | 8/2/2022 | $0 |
| | 2022 | 2022 | ADRX, INC. | 515 MARIN ST # 314 | THOUSAND OAKS | CA | 91360-4259 | VENTURA | USA | R43GM145259 | Therapeutic Immunodepletion of a Transthyretin Aggregation Intermediate | 000 | 1 | NIH | 5/31/2022 | $256,083 |
| | 2022 | 2022 | ADRX, INC. | 515 MARIN ST # 314 | THOUSAND OAKS | CA | 91360-4259 | VENTURA | USA | R43AG073018 | Brain-penetrant chemical disaggregators of tau fibrils as therapeutics for Alzheimer's Disease | 000 | 1 | NIH | 7/22/2022 | $476,551 |
| | 2022 | 2022 | ADRX, INC. | 515 MARIN ST # 314 | THOUSAND OAKS | CA | 91360-4259 | VENTURA | USA | R43TR004056 | Development of a Blood-based Diagnostic for Early Detection of Transthyretin Amyloidosis | 000 | 1 | NIH | 7/29/2022 | $270,276 |
|
|
